Loading clinical trials...

Long-term Effect of Lanthanum Carbonate on Bone | Clinical Trials | Clareo Health

COMPLETED

Long-term Effect of Lanthanum Carbonate on Bone

A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309

NCT00557323•Shire

View on ClinicalTrials.gov

Summary

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Any patient who had exposure to lanthanum carbonate in SPD405-309

Locations (19)

Imperial care Dialysis Center

Lynwood, California, United States

Barnett Research and Communications Medical Group

Torrance, California, United States

Western new England Renal & Transplant Associates

Springfield, Massachusetts, United States

Mercy Medical Center

Canton, Ohio, United States

Hypertension & Nephrology, Inc.

Providence, Rhode Island, United States

Nephrology Associates, PC

Nashville, Tennessee, United States

University of Vermont

Burlington, Vermont, United States

Nephrology Associates, PC

Richmond, Virginia, United States

Bad König, Hesse, Germany

KfH Zentrum

Aachen, Germany

Key Dates

Start Date

March 15, 2007

Primary Completion Date

August 31, 2010

Completion Date

August 31, 2010

Last Updated

July 13, 2021

Enrollment

ACTUAL participants

Conditions

Hyperphosphatemia

Interventions

Lanthanum carbonate

DRUG

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472

HyperphosphatemiaChronic Kidney Disease, Receiving Dialysis+2 more

View study

COMPLETEDPHASE3

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

NCT05085275

Anemia, Iron DeficiencyHyperphosphatemia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 13, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long-term Effect of Lanthanum Carbonate on Bone

Inclusion Criteria

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease

Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolytes

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices